Download  full announcement Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has received a clinical laboratory

NEW YORK, June 12, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announced that it has received a

Download  full announcement   Renalytix AI plc  (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that results from a

Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has yesterday

Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that its wholly-owned

Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially

NEW YORK, May 18, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has

Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and

Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law

Download  full announcement Proposed capital reduction and notice of General Meeting Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces that a circular (a “Circular”) will today be sent to